Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors With Statin for ACS Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.

Also called NCT07736313

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07736313
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07736313. Non-randomized; no masking; primary purpose treatment. Start 2026-07-01 (anticipated); primary completion 2028-09-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors With Statin for ACS Patients
Condition
Acute Coronary Syndromes
Intervention (Drug)
PCSK9 inhibitor plus rosuvastatin 20 mg tab
Intervention (Drug)
Rosuvastatin 20 Mg Oral Tablet
Lead sponsor
Assiut University (class: other)

Record details

Record id
cardio:ct-nct07736313
Content hash
e37ddf2b4f51e08d7ce31d4669f3f005e1125b013e3f431bcf815c2e275868a0